COMPARISON OF TREATMENT OUTCOME OF ANTIHYPERTENSIVE DRUGS IN THE MANAGEMENT OF PREGNANCY INDUCED HYPERTENSION
Keywords:Antihypertensive drugs, Methyldopa, Nifedipine
This study was aimed to find out the differences in the pregnancy outcome of PIH women treated with the antihypertensive drugs methyldopa and nifedipine. The prospective observational study was conducted in a multi specialty hospital at Coimbatore with 161 PIH diagnosed women. Women were categorised into the no-drug group, methyldopa group, nifedipine group and methyldopa with nifedipine group. All the women were monitored from diagnosis to delivery. The maternal and neonatal data were collected and analysed. The drugs were significantly controlled the blood pressure (BP) from base to end (P<0.001). There was no significant difference in the reduction of BP between the drugs. Cesarean delivery (>90%) and preterm delivery were high across all the groups. No significant difference was seen between these groups. The AGA (Average for gestational age) babies were significantly higher with a no-drug group (83%) and lower with nifedipine group (40%). Two women were reported with HELLP syndrome in methyldopa with nifedipine group. No significant difference was found in terms of pregnancy outcome between these groups except for eclampsia and AGA. Eclampsia was affected more with 14% in methyldopa with nifedipine group. We found similar outcomes; there were no significant changes between methyldopa, nifedipine, and the no-drug treatment. The antihypertensive drugs nifedipine and methyldopa both were significantly reduced the BP. The maternal and neonatal complications were similar between these two drugs. No beneficial effect can be identified one over another.
Ghulmiyya L, Sibai B. Maternal mortality from preeclampsia/ eclampsia. Semin Perinatol 2012;36:56-9.
Walker JJ. Pre-eclampsia. Lancet 2000;356:1260-5.
Blake S, MacDonald D. The prevention of the maternal manifestations of preeclampsia by intensive antihypertensive treatment. Br J Obstet Gynecol 1991;98:244â€“8.
Podymow T, August P. Antihypertensive drugs in pregnancy. Semin Nephrol 2011;31:70â€“85.
Jayawardana J, Lekamage N. A comparison of nifedipine with methyldopa in pregnancy induced hypertension. Celon Med J 1994;39:87-90.
Montan S, Anandakumar C, Arulkumaran S, Ingemarsson I, Ratnam SS. Effects of methyldopa on uteroplacental and fetal hemodynamics in pregnancy-induced hypertension. Am J Obstet Gynecol 1993;168:152-6.
Qasim A, Siddiqui MH, Salam JU, Nusrat U. Labetalol versus methyldopa: efficacy in pregnancy induced hypertension. Gomal J Med Sci 2014;12:233-6.
Deepanjali Lomte. An open-label, prospective, single-center study to evaluate the efficacy of methyldopa and labetalol in the treatment of patients with pregnancy-induced hypertension. World J Pharm Pharm Sci 2015;4:1235-41.
Jayasutha J, Ismail AM, Senthamarai R. Evaluation of the efficacy of methyldopa monotherapy and combination of therapy with nifedipine in pregnancy-induced hypertension. Der Pharm Lett 2011;3:383-7.
Ganeshan S, Narmadha MP, Paranjothy, Lakshminarayanan B, Alin, Bose J, et al. Comparison between nifedipine and methyldopa on blood pressure and fetal outcome in pre-eclampsia. Int J Adv Pharm Biol Sci 2012;2:191-8.
Sibai BM, Mabie WC, Shamsa F, Villar MA, Anderson GD. A Comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. Am J Obstet Hynecol 1990;162:966-7.
Levin AC, Doering PL, Hatton RC. Use of nifedipine in the hypertensive diseases of pregnancy. Ann Pharmacother 1994;28:1371-8.
Suhonen L, Teramo K. Hypertension and pre-eclampsia in women with gestational glucose tolerance. Acta Obstet Gynecol Scand 1993;72:269-72.
Elhassan EM, Mirghani OA, Habour AB, Adam I. Methyldopa versus no drug treatment in the management of mild preeclampsia. East Afr Med J 2002;79:172-5.
Venkateswaramurthy N, John C, Perumal P. Study on anti-hypertensives in preeclampsia. Asian J Pharm Clin Res 2012;5:126-8.
Anderson NR, Undeberg M, Bastianelli KMS. Pregnancy-induced hypertension and preeclampsia: a review of current antihypertensive pharmacologic treatment options. Austin J Pharmacol Ther 2013;1:1-8.